Article Text

Download PDFPDF
EP829 The need for and the development of a decision aid for primary treatment of advanced stage ovarian cancer patients
  1. JE den Ouden1,
  2. R The2,
  3. BJ Myren1,
  4. D Boll3,
  5. WJ van Driel4,
  6. RI Lalisang5,6,
  7. RFPM Kruitwagen6,7 and
  8. AM van Altena1
  1. 1Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen
  2. 2ZorgKeuzeLab, Delft
  3. 3Obstetrics and Gynaecology, Catharina Hospital, Eindhoven
  4. 4Gynaecologic Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam
  5. 5Internal Medicine, Division Medical Oncology, Maastricht University Medical Center
  6. 6School for Oncology and Developmental Biology, GROW
  7. 7Obstetrics and Gynaecology, Maastricht University Medical Center, Maastricht, The Netherlands


Introduction/Background In the light of the growing number of (intense) treatment options for advanced stage ovarian cancer (OC) patients, while survival is still poor, the patient association indicated an increased need for a tool to improve shared-decision-making (SDM) by patients and their clinicians. The Dutch working party on gynaecologic oncology initiated the development of an evidence based online decision aid (DA) to support SDM. The aim of this study was to develop the DA.

Methodology A four-stage development method was followed: 1: Identifying patients‘ (N=43) and professionals’ (N=22) needs by questionnaires and in-depth patient interviews (N=12). 2: Face-to-face meetings with a multidisciplinary team were organized including representatives of the patient association. 3: Development of the DA using International Patient Decision Aid Standards (IPDAS) and Dutch Guidelines. 4: Usability testing with OC patients and professionals.

Results Both patients and clinicians supported the need for reliable information that include all available treatment options in the Netherlands. Although the majority of patients were very satisfied about the process of information provision, 90% indicated that no choice in treatment options was offered. Based on study findings and discussions during the meetings, a consultation sheet and a DA were developed. The sheet, presented during first consultations, contains a summary of all treatment options, including intraperitoneal (IP)-chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC), and a login code for the online DA. The online part, which can be used at home, consists of information about disease and treatment options, questions about quality of life and treatment preferences, and ends in a summary which patient and clinician can discuss during the next consultation.

Conclusion A DA was developed in cooperation with patients and professionals to support SDM for advanced stage OC patients and their clinicians. Acceptance was gained among all stakeholders involved. The DA is currently under assessment in a multicenter implementation trial.

Disclosure Ir. Regina The is the managing director of ZorgKeuzeLab B.V. Delft.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.